These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 30216039)

  • 41. Noribogaine is a G-protein biased κ-opioid receptor agonist.
    Maillet EL; Milon N; Heghinian MD; Fishback J; Schürer SC; Garamszegi N; Mash DC
    Neuropharmacology; 2015 Dec; 99():675-88. PubMed ID: 26302653
    [TBL] [Abstract][Full Text] [Related]  

  • 42. 18-Methoxycoronardine attenuates nicotine-induced dopamine release and nicotine preferences in rats.
    Glick SD; Maisonneuve IM; Visker KE; Fritz KA; Bandarage UK; Kuehne ME
    Psychopharmacology (Berl); 1998 Oct; 139(3):274-80. PubMed ID: 9784085
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Unique and potent effects of acute ibogaine on zebrafish: the developing utility of novel aquatic models for hallucinogenic drug research.
    Cachat J; Kyzar EJ; Collins C; Gaikwad S; Green J; Roth A; El-Ounsi M; Davis A; Pham M; Landsman S; Stewart AM; Kalueff AV
    Behav Brain Res; 2013 Jan; 236(1):258-269. PubMed ID: 22974549
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of ibogaine and noribogaine on the antinociceptive action of mu-, delta- and kappa-opioid receptor agonists in mice.
    Bhargava HN; Cao YJ; Zhao GM
    Brain Res; 1997 Mar; 752(1-2):234-8. PubMed ID: 9106462
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ibogaine and Subjective Experience: Transformative States and Psychopharmacotherapy in the Treatment of Opioid Use Disorder.
    Brown TK; Noller GE; Denenberg JO
    J Psychoactive Drugs; 2019; 51(2):155-165. PubMed ID: 30967101
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A contemporary history of ibogaine in the United States and Europe.
    Alper KR; Beal D; Kaplan CD
    Alkaloids Chem Biol; 2001; 56():249-81. PubMed ID: 11705112
    [No Abstract]   [Full Text] [Related]  

  • 47. Ibogaine and the inhibition of acetylcholinesterase.
    Alper K; Reith ME; Sershen H
    J Ethnopharmacol; 2012 Feb; 139(3):879-82. PubMed ID: 22200647
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mechanisms of Antiaddictive Actions of Ibogaine
    Glick SD; Maisonneuve IM
    Ann N Y Acad Sci; 1998 May; 844(1):214-226. PubMed ID: 29090809
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Extraction studies of Tabernanthe iboga and Voacanga africana.
    Jenks CW
    Nat Prod Lett; 2002 Feb; 16(1):71-6. PubMed ID: 11942686
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Remission of Severe Opioid Use Disorder with Ibogaine: A Case Report.
    Cloutier-Gill L; Wood E; Millar T; Ferris C; Eugenia Socias M
    J Psychoactive Drugs; 2016; 48(3):214-7. PubMed ID: 27192438
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluating the toxicity and therapeutic potential of ibogaine in the treatment of chronic opioid abuse.
    Luz M; Mash DC
    Expert Opin Drug Metab Toxicol; 2021 Sep; 17(9):1019-1022. PubMed ID: 34139922
    [No Abstract]   [Full Text] [Related]  

  • 52. Ibogaine-like effects of noribogaine in rats.
    Glick SD; Pearl SM; Cai J; Maisonneuve IM
    Brain Res; 1996 Mar; 713(1-2):294-7. PubMed ID: 8725004
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Psychedelic Treatments for Substance Use Disorder and Substance Misuse: A Mixed Methods Systematic Review.
    Sharma R; Batchelor R; Sin J
    J Psychoactive Drugs; 2023; 55(5):612-630. PubMed ID: 36933948
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dark Classics in Chemical Neuroscience: Mescaline.
    Cassels BK; Sáez-Briones P
    ACS Chem Neurosci; 2018 Oct; 9(10):2448-2458. PubMed ID: 29847089
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Structure-activity relationship of ibogaine analogs interacting with nicotinic acetylcholine receptors in different conformational states.
    Arias HR; Feuerbach D; Targowska-Duda KM; Jozwiak K
    Int J Biochem Cell Biol; 2011 Sep; 43(9):1330-9. PubMed ID: 21642011
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures.
    Mash DC; Kovera CA; Pablo J; Tyndale RF; Ervin FD; Williams IC; Singleton EG; Mayor M
    Ann N Y Acad Sci; 2000 Sep; 914():394-401. PubMed ID: 11085338
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Drug discrimination studies with ibogaine.
    Helsley S; Rabin RA; Winter JC
    Alkaloids Chem Biol; 2001; 56():63-77. PubMed ID: 11705117
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dark Classics in Chemical Neuroscience: N, N-Dimethyltryptamine (DMT).
    Cameron LP; Olson DE
    ACS Chem Neurosci; 2018 Oct; 9(10):2344-2357. PubMed ID: 30036036
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Receptor binding profile suggests multiple mechanisms of action are responsible for ibogaine's putative anti-addictive activity.
    Sweetnam PM; Lancaster J; Snowman A; Collins JL; Perschke S; Bauer C; Ferkany J
    Psychopharmacology (Berl); 1995 Apr; 118(4):369-76. PubMed ID: 7568622
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Interactions between iboga agents and methamphetamine sensitization: studies of locomotion and stereotypy in rats.
    Szumlinski KK; Balogun MY; Maisonneuve IM; Glick SD
    Psychopharmacology (Berl); 2000 Aug; 151(2-3):234-41. PubMed ID: 10972470
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.